IL37 and neoplasm: IL-37 has been shown to enhance anti-tumour activity in hepatocellular carcinoma via indirectly recruiting and activating dendritic cells via IL-12 and IL-18 (43), and subsequently via perforin and the FAS-L pathway (63).